Camellia Plc (CAM)
London Exchange · UK · prices in GBX · close of 20 Oct 2026
Key indicators
| Last close | GBX 5,725.00 |
|---|---|
| 52-week range | 4,578.13 – 6,008.80 |
| Return, 1 month / 3 months | +1.3% / +6.0% |
| Return, 1 year / 3 years | +0.9% / +38.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 50 |
| Volatility (1 year) | 27.8% |
| Worst drawdown (1 year) | -19.5% |
| Average daily value traded | 3.59M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Camellia Plc is a British agriculture and horticulture group based in Kent. It grows and processes tea on estates in South Asia and Africa, and also produces other crops and horticultural products. Alongside farming, the company owns engineering and food businesses that supply machinery and food ingredients to industrial and consumer customers. Its operations span several countries, with management and trading activities run from its base in the United Kingdom.
The shares are listed on the London Exchange in UK under the code CAM, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Camellia Plc (CAM) trades on the London Exchange in UK. It last closed at GBX 5,725.00 on 20 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 1,125 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.9% and over the last three months it rose 6.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.9% | ||
| From 52-week high | -3.8% | ||
| Momentum | 55 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.0% | ||
| 6-month return | 2.2% | ||
| 12-month return, skipping the last month | -0.4% | ||
| Stability (higher is calmer) | 71 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.5% | ||
| Liquidity | 65 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.59M GBX | ||
| Zero-volume days | 3.3% | ||
| Income | 16 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +1.3% |
| 3 months | +6.0% |
| 6 months | +2.2% |
| 1 year | +0.9% |
| 3 years | +38.8% |
| 5 years | −1.5% |
Signals
| 50-day / 200-day average | 5,742.50 / 5,257.36 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 191.40 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jul 2026 | GBP 2.6000 |
| 3 Jul 2025 | GBP 2.6000 |
| 14 Sep 2023 | GBP 0.4400 |
| 15 Jun 2023 | GBP 1.0200 |
| 8 Sep 2022 | GBP 0.4400 |
| 7 Jul 2022 | GBP 1.0200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.